TY - JOUR
T1 - Brain metabolic changes in hodgkin disease patients following diagnosis and during the disease course
T2 - An 18F-FDG PET/CT study
AU - Chiaravalloti, Agostino
AU - Pagani, Marco
AU - Cantonetti, Maria
AU - Di Pietro, Barbara
AU - Tavolozza, Mario
AU - Travascio, Laura
AU - Di Biagio, Daniele
AU - Danieli, Roberta
AU - Schillaci, Orazio
PY - 2015/2/1
Y1 - 2015/2/1
N2 - The aim of the present study was to investigate brain glucose metabolism in patients with Hodgkin disease (HD) after diagnosis and during chemotherapy treatment. Following the administration of first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy, 74 HD patients underwent 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography brain scans, both baseline (PET0) and interim (PET2) at the Department of Biomedicine and Prevention, University of Rome Tor Vergata (Rome, Italy). Fifty-seven patients were further evaluated 15±6 days after four additional cycles (PET6). Furthermore, a control group (CG) of 40 chemotherapy-naïve subjects was enrolled. Differences in brain 18F-FDG uptake between the CG, PET0, PET2 and PET6 scans were analyzed using statistical parametric mapping. Compared with the PET0 and CG scans, the PET2 scan demonstrated a higher metabolic activity in Brodmann area (BA) 39, and a metabolic reduction in BA 11 bilaterally and in left BA 32. All of these changes disappeared at PET6. The results of the present study indicate that ABVD chemotherapy has a limited impact on brain metabolism.
AB - The aim of the present study was to investigate brain glucose metabolism in patients with Hodgkin disease (HD) after diagnosis and during chemotherapy treatment. Following the administration of first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy, 74 HD patients underwent 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography brain scans, both baseline (PET0) and interim (PET2) at the Department of Biomedicine and Prevention, University of Rome Tor Vergata (Rome, Italy). Fifty-seven patients were further evaluated 15±6 days after four additional cycles (PET6). Furthermore, a control group (CG) of 40 chemotherapy-naïve subjects was enrolled. Differences in brain 18F-FDG uptake between the CG, PET0, PET2 and PET6 scans were analyzed using statistical parametric mapping. Compared with the PET0 and CG scans, the PET2 scan demonstrated a higher metabolic activity in Brodmann area (BA) 39, and a metabolic reduction in BA 11 bilaterally and in left BA 32. All of these changes disappeared at PET6. The results of the present study indicate that ABVD chemotherapy has a limited impact on brain metabolism.
KW - Adriamycin
KW - Bleomycin
KW - Chemobrain
KW - Chemotherapy
KW - Hodgkin disease
KW - Positron emission tomography
KW - Vinblastine and dacarbazine
UR - http://www.scopus.com/inward/record.url?scp=84918802712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84918802712&partnerID=8YFLogxK
U2 - 10.3892/ol.2014.2765
DO - 10.3892/ol.2014.2765
M3 - Article
AN - SCOPUS:84918802712
VL - 9
SP - 685
EP - 690
JO - Oncology Letters
JF - Oncology Letters
SN - 1792-1074
IS - 2
ER -